Small molecule · Inhibitor of NUAK family SNF1-like kinase 1 (ARK5) (NUAK1), cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Traws Pharma
Narazaciclib is an orally bioavailable kinase inhibitor that binds and inhibits NUAK1 (ARK5), CDK4 and CDK6. By blocking CDK4/6-mediated phosphorylation of the retinoblastoma protein in early G1, it causes G1 cell cycle arrest. It is being studied in solid tumors and endometrioid endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05705505 | Phase 1/2 | Endometrioid Endometrial Cancer | Unknown | TRAW |
| NCT04739293 | Phase 1 | Solid Tumors, Adult | Unknown | TRAW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrioid Endometrial CancerSolid Tumors, Adult
Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.
See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRAW catalysts and pipeline →